6% Hetastarch In 0.9% Sodium Chloride Injection, Solution
NDC Package 51662-1317-3
Package Information
6% Hetastarch In 0.9% Sodium Chloride injection is indicated in the treatment of hypovolemia when plasma volume expansion is desired. This formulation utilizes a injection, solution delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1317 and is authorized under FDA application BA740193.
Identification & Billing
- RxCUI: 310757 - hetastarch 6 % in 500 ML Injection
- RxCUI: 310757 - 500 ML hetastarch 60 MG/ML Injection
- RxCUI: 310757 - hetastarch 6 % per 500 ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51662 - Hf Acquisition Co Llc, Dba Healthfirst
- 51662-1317 - 6% Hetastarch In 0.9% Sodium Chloride
- 51662-1317-3 - 12 CONTAINER in 1 CASE / 500 mL in 1 CONTAINER (51662-1317-2)
- 51662-1317 - 6% Hetastarch In 0.9% Sodium Chloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51662-1317). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51662-1317-3 identifies a specific commercial package of 12 container in 1 case / 500 ml in 1 container (51662-1317-2) of 6% Hetastarch In 0.9% Sodium Chloride, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This injection, solution is formulated for intravenous use and contains hetastarch as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on November 26, 2018. The current certification is valid through December 31, 2026.
How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662131703. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.